Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences r&d expenses
Research and development expenses are spending on new products and technology.
Pacira BioSciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $121.73M, up 26.1% year over year. For fiscal 2025 it was $117.31M, up 43.8% from the year before. Over ten years it grew 15.1% a year on average. The highest annual figure on record is $117.31M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.31M | +43.8% |
| FY2024 | Dec 31, 2024 | $81.58M | +7.0% |
| FY2023 | Dec 31, 2023 | $76.26M | -10.1% |
| FY2022 | Dec 31, 2022 | $84.80M | +52.7% |
| FY2021 | Dec 31, 2021 | $55.55M | -6.5% |
| FY2020 | Dec 31, 2020 | $59.42M | -17.6% |
| FY2019 | Dec 31, 2019 | $72.12M | +29.5% |
| FY2018 | Dec 31, 2018 | $55.69M | -2.8% |
| FY2017 | Dec 31, 2017 | $57.29M | +25.4% |
| FY2016 | Dec 31, 2016 | $45.68M | +59.4% |
| FY2015 | Dec 31, 2015 | $28.66M | +53.0% |
| FY2014 | Dec 31, 2014 | $18.73M | -13.1% |
| FY2013 | Dec 31, 2013 | $21.56M | +117.0% |
| FY2012 | Dec 31, 2012 | $9.94M | -33.2% |
| FY2011 | Dec 31, 2011 | $14.87M | -20.2% |
| FY2010 | Dec 31, 2010 | $18.63M | -29.0% |
| FY2009 | Dec 31, 2009 | $26.23M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $30.24M | +7.2% |
| Q1 FY2026 | Mar 31, 2026 | $28.07M | +10.8% |
| Q4 FY2025 | Dec 31, 2025 | $37.45M | +56.7% |
| Q3 FY2025 | Sep 30, 2025 | $25.97M | +35.9% |
| Q2 FY2025 | Jun 30, 2025 | $28.20M | +38.7% |
| Q1 FY2025 | Mar 31, 2025 | $25.34M | +39.0% |
| Q4 FY2024 | Dec 31, 2024 | $23.90M | +22.8% |
| Q3 FY2024 | Sep 30, 2024 | $19.10M | -8.3% |
| Q2 FY2024 | Jun 30, 2024 | $20.34M | +8.0% |
| Q1 FY2024 | Mar 31, 2024 | $18.24M | +6.4% |
| Q4 FY2023 | Dec 31, 2023 | $19.46M | +11.2% |
| Q3 FY2023 | Sep 30, 2023 | $20.83M | +7.3% |
| Q2 FY2023 | Jun 30, 2023 | $18.82M | -28.4% |
| Q1 FY2023 | Mar 31, 2023 | $17.14M | -20.7% |
| Q4 FY2022 | Dec 31, 2022 | $17.51M | +12.8% |
| Q3 FY2022 | Sep 30, 2022 | $19.41M | +67.6% |
| Q2 FY2022 | Jun 30, 2022 | $26.28M | +109.0% |
| Q1 FY2022 | Mar 31, 2022 | $21.61M | +36.1% |
| Q4 FY2021 | Dec 31, 2021 | $15.51M | +1.2% |
| Q3 FY2021 | Sep 30, 2021 | $11.58M | -21.0% |
| Q2 FY2021 | Jun 30, 2021 | $12.57M | -7.7% |
| Q1 FY2021 | Mar 31, 2021 | $15.88M | +0.4% |
| Q4 FY2020 | Dec 31, 2020 | $15.33M | -22.0% |
| Q3 FY2020 | Sep 30, 2020 | $14.65M | -27.7% |
| Q2 FY2020 | Jun 30, 2020 | $13.62M | -23.6% |
| Q1 FY2020 | Mar 31, 2020 | $15.82M | +10.0% |
| Q4 FY2019 | Dec 31, 2019 | $19.65M | +38.7% |
| Q3 FY2019 | Sep 30, 2019 | $20.26M | +36.0% |
| Q2 FY2019 | Jun 30, 2019 | $17.83M | +45.7% |
| Q1 FY2019 | Mar 31, 2019 | $14.38M | +0.0% |
| Q4 FY2018 | Dec 31, 2018 | $14.17M | +41.3% |
| Q3 FY2018 | Sep 30, 2018 | $14.90M | +26.5% |
| Q2 FY2018 | Jun 30, 2018 | $12.24M | -35.1% |
| Q1 FY2018 | Mar 31, 2018 | $14.38M | -13.6% |
| Q4 FY2017 | Dec 31, 2017 | $10.03M | -41.3% |
| Q3 FY2017 | Sep 30, 2017 | $11.78M | +20.7% |
| Q2 FY2017 | Jun 30, 2017 | $18.86M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $17.07M | – |
| Q3 FY2016 | Sep 30, 2016 | $9.75M | – |
See a number that looks wrong?